Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AbbVie is conducting a clinical study titled A Prospective, Multicenter Clinical Study to Evaluate the Safety and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Subjects With Glaucoma. The study aims to assess the safety and effectiveness of the XEN63 gel stent in managing intraocular pressure in glaucoma patients, a leading cause of blindness worldwide. This study is significant as it explores alternative surgical approaches for patients who have not responded to conventional treatments.
The intervention being tested is the XEN63 Glaucoma Treatment System, a gel stent designed to reduce intraocular pressure. It is being evaluated in two different surgical approaches: ab interno (inside the eye) and ab externo (outside the eye).
The study is interventional, with a parallel assignment model and double masking involving participants and outcomes assessors. Its primary purpose is treatment, focusing on the effectiveness of the XEN63 gel stent in glaucoma management.
The study began on February 11, 2025, with the latest update submitted on June 30, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders.
The market implications of this study could be significant for AbbVie’s stock performance, as successful results may enhance the company’s position in the glaucoma treatment market. The study’s outcomes could influence investor sentiment and potentially affect competitor dynamics within the industry.
The study is ongoing, with further details available on the ClinicalTrials portal.